Elevance Health (ELV) underperformed in Q1 2026, closing at $395.18 with an $85.81 billion market cap after a one-month loss of 1.86%.
Elevance Health Inc. (NYSE:ELV) weighed on the Heartland Opportunistic Value Equity Strategy’s performance in Q1 2026, closing at $395.18 per share on June 26, 2026. The company’s market capitalization stood at $85.81 billion, with shares posting a one-month return of -1.86% despite a 1.60% gain over the past 52 weeks.
The broader healthcare sector faced headwinds during the quarter, contributing to ELV’s underperformance. The strategy, which focuses on bottom-up fundamental analysis, still outperformed the Russell 3000 Value Index, rising 3.66% compared to the index’s 2.23% gain.
Heartland Advisors noted that stock selection was positive across most sectors, though ELV detracted from overall results. The firm emphasized its avoidance of geopolitical speculation, instead prioritizing company-specific fundamentals.